



**AmideBio to present a novel treatment for hyperinsulinism at the International Congenital Hyperinsulinism Conference July 15-16, 2017 at the Stockton Seaview Hotel, Galloway, New Jersey.**

**BOULDER, CO, June 26, 2017** – AmideBio, LLC, a privately-held biopharmaceutical company, today announced that AmideBio’s Chief Technology Officer, Dr. Michael H. B. Stowell will present a talk titled **“Novel Pumpable Glucagons for Treatment of Hyperinsulinism”** at the 2017 International Congenital Hyperinsulinism Conference July 15-16, 2017, hosted by the Children’s Hospital of Philadelphia (CHOP) and Congenital Hyperinsulinism International (CHI), a charitable organization dedicated to improving the lives of children, adults, and families living with congenital hyperinsulinism.

“The presentation will describe the results of one of AmideBio’s programs in the diabetes field and exemplifies the Company’s transition from early stage discovery to drug targets ready for clinical study,” said Dr. Misha Plam, AmideBio’s President and CEO. “The novel soluble glucagons that will be described have great potential in the quest for the treatment of congenial hyperinsulinism.”

Congenital hyperinsulinism is a rare condition characterized by persistent hypoglycemia in children and newborns with an incidence of approximately 1/50,000 births in the United States. Children with this condition are at high risk of hypoglycemic seizures and permanent brain injury. A soluble form of glucagon that is stable long-term would be of great benefit to patients who fail to respond to current drug treatments. Importantly, a long-term glucagon treatment regime has the potential to eliminate the need for a total pancreatectomy in babies with medically-unresponsive hyperinsulinism.

#### **About AmideBio:**

AmideBio is a biotechnology company leveraging its proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides cost effectively to the pharmaceutical and biotech industry, while also building a pipeline of novel biotherapeutics. AmideBio's proprietary technology enables the rapid and economical manufacture of peptides of any length with unprecedented purity.. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.

#### **Contact:**

Dr. Misha Plam  
President and CEO

T: (303) 641-3669

[misha.plam@amidebio.com](mailto:misha.plam@amidebio.com)

[www.amidebio.com](http://www.amidebio.com)

###